Among the most successful technologies have been particle size reduction to nanometer-size drug crystals with greater surface area for dissolution, production of amorphous solid dispersions for reducing the energy required for dissolution, nanoparticle systems for dissolving/dispersing a hydrophobic drug in either a lipid or polymer material, and the use of to dissolve a drug in an oil phase of an oil-in-water system. Ascendia was established to provide pharmaceutical companies with a contract research partner that can provide all of these technologies in order to efficiently determine which approach is most suitable for a given molecule. Drug Development & Delivery recently interviewed Jingjun (Jim) Huang, PhD, CEO and Founder of Ascendia, to discuss the company’s unique vision and strategy.